Certara (CERT) Projected to Post Earnings on Wednesday

Certara (NASDAQ:CERT - Get Free Report) is projected to release its Q2 2025 earnings data after the market closes on Wednesday, August 6th. Analysts expect Certara to post earnings of $0.11 per share and revenue of $104.14 million for the quarter.

Certara (NASDAQ:CERT - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of $0.10 by $0.04. The firm had revenue of $106.00 million for the quarter, compared to analysts' expectations of $104.44 million. Certara had a positive return on equity of 5.05% and a negative net margin of 0.67%. The company's quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.10 earnings per share. On average, analysts expect Certara to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Certara Trading Down 3.0%

Shares of CERT traded down $0.30 during mid-day trading on Friday, reaching $9.54. 1,930,936 shares of the company's stock traded hands, compared to its average volume of 1,485,978. The stock has a market cap of $1.55 billion, a P/E ratio of -477.00 and a beta of 1.42. The stock's 50-day moving average is $11.04 and its two-hundred day moving average is $11.83. Certara has a 12 month low of $8.64 and a 12 month high of $15.69. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.78 and a quick ratio of 2.78.

Institutional Trading of Certara

Hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC purchased a new stake in Certara during the first quarter worth $259,000. Goldman Sachs Group Inc. lifted its holdings in shares of Certara by 65.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company's stock valued at $2,267,000 after purchasing an additional 90,724 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of Certara by 17.1% during the 1st quarter. Jane Street Group LLC now owns 277,054 shares of the company's stock valued at $2,743,000 after purchasing an additional 40,463 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Certara by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company's stock valued at $2,965,000 after purchasing an additional 35,954 shares during the last quarter. Hedge funds and other institutional investors own 73.96% of the company's stock.

Analysts Set New Price Targets

CERT has been the topic of several research analyst reports. Robert W. Baird increased their price objective on Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. KeyCorp dropped their price objective on Certara from $18.00 to $15.00 and set an "overweight" rating on the stock in a research note on Monday, July 14th. JMP Securities reissued a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. Morgan Stanley initiated coverage on Certara in a research note on Thursday, July 3rd. They issued an "equal weight" rating and a $16.00 price objective on the stock. Finally, Barclays raised Certara from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $11.00 to $14.00 in a research note on Thursday, May 8th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $15.29.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.